Michael Caligiuri

30PUBLICATIONS
83CO-AUTHORS
Innate immunityCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsMedical mycologyInfectious diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (30)

|Feb 04, 2026
Human type-1 innate lymphoid cells control leukemia stem cell differentiation and limit acute myeloid leukemia development.

Zhenlong Li, Rui Ma, Hejun Tang

|Jan 06, 2026
Optimizing In Vivo CAR T-cell Engineering for Cancer Immunotherapy.

Ruiheng Wang, Jianhua Yu, Michael A Caligiuri

|Dec 19, 2025
No BCMA? No Problem: A CD70-Targeting CAR-NK Cell Shows Promise in High-risk Myeloma.

Don M Benson, Michael A Caligiuri

|Sep 10, 2025
Comparative efficacy and safety of PSCA CAR-engineered Vδ1 γδ T cells for immunotherapy of pancreatic cancer.

Zhixin Li, Ningyuan Liu, Zahir Shah

|Aug 18, 2025
Loss of YTHDF2 enhances Th9 programming and CAR-Th9 cell antitumor efficacy.

Sai Xiao, Songqi Duan, Yaqun Hong

|Feb 01, 2025
miR-142 deficit in T cells during blast crisis promotes chronic myeloid leukemia immune escape.

Fang Chen, Dandan Zhao, Yongfang Xu

Pageof 5

Frequent Collaborators

20 joint publications

Jianhua Yu

7 joint publications

Tasha Barr

6 joint publications

Shoubao Ma

5 joint publications

Guido Marcucci